Afficher la notice abrégée

Prescriber and institutional barriers and facilitators of clozapine use: A systematic review

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorVERDOUX, Helene
IDREF: 115951903
dc.contributor.authorQUILES, Clelia
dc.contributor.authorBACHMANN, C. J.
dc.contributor.authorSISKIND, D.
dc.date.accessioned2021-01-06T11:22:24Z
dc.date.available2021-01-06T11:22:24Z
dc.date.issued2018-11
dc.identifier.issn1573-2509 (Electronic) 0920-9964 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/23702
dc.description.abstractEnBACKGROUND: As clozapine is under-prescribed in persons with treatment-resistant schizophrenia (TRS), it is necessary to better identify the determinants of health inequalities in access to clozapine use. OBJECTIVE: To identify mental health professionals' characteristics or attitudes and institutional characteristics facilitating or limiting clozapine prescribing. METHOD: We systematically searched multiple electronic databases for articles reporting: (i) mental health professionals' attitudes and characteristics favoring or limiting clozapine prescribing; (ii) institutional characteristics associated with variations in clozapine prescribing; (iii) interventions aimed at enhancing clozapine prescribing. Data were synthesized narratively. RESULTS: A total of 31 articles reporting findings of 29 studies published from 1993 to 2017 in 11 countries fulfilled our inclusion criteria. The main prescriber-related barriers to clozapine prescribing are lack of personal prescribing experience and concern with pharmacological characteristics of clozapine (blood monitoring and adverse effects). Lack of knowledge about the effectiveness of clozapine does not appear as a major determinant of under-prescription. Institutional-related characteristics favoring clozapine prescribing are prescribers' adherence to evidence-based medicine principles and learning by modelling from experienced clozapine prescribers. CONCLUSION: Effective strategies to increase access to clozapine in persons with TRS include implementation of integrated clozapine clinics, simplification of blood monitoring, education for prescribers and contact with experienced prescribers. Programs addressing barriers in clozapine prescription need to be disseminated more broadly to ensure persons with TRS have access to evidenced based treatments such as clozapine. Inequality in access to clozapine care should be more systematically handled by mental health facilities and health regulatory agencies.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.title.enPrescriber and institutional barriers and facilitators of clozapine use: A systematic review
dc.title.alternativeSchizophr Resen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.schres.2018.05.046en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29880453en_US
bordeaux.journalSchizophrenia Researchen_US
bordeaux.page10-19en_US
bordeaux.volume201en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03194146
hal.version1
hal.date.transferred2021-04-09T11:07:14Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Schizophrenia%20Research&rft.date=2018-11&rft.volume=201&rft.spage=10-19&rft.epage=10-19&rft.eissn=1573-2509%20(Electronic)%200920-9964%20(Linking)&rft.issn=1573-2509%20(Electronic)%200920-9964%20(Linking)&rft.au=VERDOUX,%20Helene&QUILES,%20Clelia&BACHMANN,%20C.%20J.&SISKIND,%20D.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée